OncoMatch/Clinical Trials/NCT07169500
Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
Is NCT07169500 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CAR-T for multiple myeloma.
Treatment: CAR-T — Evaluate and compare the safety and efficacy of BCMA-CART ± ASCT in the treatment of newly diagnosed multiple myeloma (NDMM) in young patients
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: car-t cell therapy
Cannot have received: bcma-targeted therapy
Lab requirements
Blood counts
Hemoglobin (Hb) ≥ 60 g/L; ANC ≥ 1.0 × 10^9/L (no G-CSF or other growth factors within 7 days prior to screening); ALC ≥ 0.5 × 10^9/L; Platelets ≥ 50 × 10^9/L (no platelet transfusion within 7 days prior to screening)
Kidney function
Creatinine clearance (CrCl) ≥ 40 ml/min
Liver function
Serum total bilirubin (TBIL) ≤ 1.5x ULN; ALT and AST ≤ 2.5x ULN
Cardiac function
LVEF ≥ 45%
Subjects must have adequate organ function and meet all of the following test results: Serum total bilirubin (TBIL) ≤ 1.5x ULN; ALT and AST ≤ 2.5x ULN; Creatinine clearance (CrCl) ≥ 40 ml/min; Prothrombin time (PT) ≤ 1.5x ULN, APTT < 1.5x ULN, INR < 1.5x ULN; Hemoglobin (Hb) ≥ 60 g/L; ANC ≥ 1.0 × 10^9/L (no G-CSF or other growth factors within 7 days prior to screening); ALC ≥ 0.5 × 10^9/L; Platelets ≥ 50 × 10^9/L (no platelet transfusion within 7 days prior to screening); LVEF ≥ 45%; SpO2 ≥ 92%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify